Investigating how neutrophils contribute to arthritis damage
Understanding A Molecular Cascade That Drives Neutrophil Mediated Pathology In Arthritis
['FUNDING_R01'] · UNIVERSITY OF VIRGINIA · NIH-11019684
This study is looking at how a type of white blood cell called neutrophils contributes to inflammation and joint damage in rheumatoid arthritis, with the hope of finding new ways to help manage symptoms for people living with the condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF VIRGINIA (nih funded) |
| Locations | 1 site (CHARLOTTESVILLE, UNITED STATES) |
| Trial ID | NIH-11019684 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of neutrophils, a type of white blood cell, in the inflammation and joint damage seen in rheumatoid arthritis (RA). By studying the molecular mechanisms that drive neutrophil activity, the researchers aim to identify new therapeutic targets that could help control the symptoms of RA. The study involves using animal models to observe how the absence of a specific protein, ELMO1, affects the severity of arthritis, which could lead to new treatment strategies for patients. If successful, this research could pave the way for more effective therapies that specifically target neutrophil function in arthritis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who experience significant inflammation and joint pain.
Not a fit: Patients with other forms of arthritis or those who do not have significant neutrophil involvement in their condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce inflammation and joint damage in rheumatoid arthritis patients.
How similar studies have performed: Previous research has shown that targeting neutrophil activity can lead to improvements in inflammatory conditions, suggesting that this approach may be promising.
Where this research is happening
CHARLOTTESVILLE, UNITED STATES
- UNIVERSITY OF VIRGINIA — CHARLOTTESVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ARANDJELOVIC, SANJA — UNIVERSITY OF VIRGINIA
- Study coordinator: ARANDJELOVIC, SANJA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.